

Integration and analysis of heterogeneous big data for precision medicine and suggested treatments for different types of patients.

http://project-iasis.eu



Coordinator: NCRS Demokritos, Greece (George Paliouras)

iASiS: Big Data to Support Precision Medicine and Public Health Policy

Maria-Esther Vidal

Leibniz Information Centre For Science and Technology University Library (TIB) and L3S Institute @ Leibniz University of Hannover (LUH), Germany



Motivation

Depression	g.	g.	9.	9.	Ä	Ř	Ä	Ä	Ä	Ř	38%
Asthma	9.	g.	9.	9.	Ä	Ŕ	Ŕ	Ä	Ä	Ŕ	40%
Cardiac Arrhythmias	g.	g.	9.	g.	Ř	Ŕ	Ä	Ť	Ñ	Ä	40%
Diabetes	g.	g.	g.	9.	Ŕ	Ŕ	Ŕ	Ä	Ä	Ŕ	43%
Migraine	9.	9.	9.	9.	9.	Ä	Ä	Ä	Ä	Ä	48%
Arthritis	g.	9.	9.	9.	9.	Ř	Ä	Ä	Ä	Ä	50%
Osteoporosis	9.	9.	9.	9.	9.	Ä	Ä	Ä	Ä	Ä	52%
Alzheimer's	9.	9.	9.	9.	9.	9.	9.	Ä	Ä	Ä	70%
Cancer	g.	9.	9.	9.	9.	9.	9.	g.	Ä	Ä	75%



[Source: Brian B. Spear, Margo Heath-Chiozzi, Jeffrey Huff, "Clinical Trends in Molecular Medicine," Volume 7, Issue 5, 1 May 2001, pages 201-204.]

Vision and Objectives

iASiS Vision:


Turn clinical, pharmacogenomics, and other **Big Data** into actionable **knowledge** for personalized medicine and health policy-making

Objectives:

- Integrate automated unstructured and structured data analysis, image analysis, and sequence analysis into a Big Data framework
- Develop a framework for supporting personalised diagnosis and treatments



Pilot 1: Lung Cancer



Motivation:

- Lung cancer among the most
 - Common and deadly diseases
 - Costly cancers
- Lung cancer is a heterogeneous disease.
 Characteristics differ among
 - Patients
 - Tumor regions

iASiS will enable:

- Discovery of correlations among tumor spread, prognosis, response to treatment
- Unraveling molecular mechanisms that predict response to different tumor types (signatures)



Pilot 2: Alzheimer's Disease



Motivation:


- Approximately, 10% of people over 65 suffer from Alzheimer's
- Heterogeneity of the symptoms impedes accurate diagnosis and treatments

iASiS will enable:

- Discovery of patterns associated with prognosis, outcomes, and response to treatments
- Association of medical and lifestyle advice with Alzheimer's risk and stages of severity



The iASiS Pipeline





How the Community can contribute?

Datasets:

Pharmacogenomics and **Clinical** datasets:

- Information about Lung cancer or Alzheimer's patients
- Clinical record data, images related to clinical records, and genomic data

Data Analytics Tools:

Data analytics tools able to

- Discovery communities of similar entities
- Predicting associations in the iASiS KG
- Determining relatedness
 between entities in iASiS KG



How iASiS will contribute to the community?

iASiS Knowledge Graph (KG)

RDF knowledge graph integrating

- Information about Lung cancer or Alzheimer's patients
- Pharmacogenomics data
- Interactions between drugs, drugs and proteins, and drugs and side effects.

Data Analytics Tools:

Data analytics tools able to

- Predict interactions between entities in the iASiS KG
- Uncover unknown patterns in patients with Lung cancer or Alzheimer's disease.



Available Tools

GADES, a **semantic similarity measure** to determine relatedness between entities in a knowledge graph

https://github.com/RDF-Molecules/GADES

semEPNode, a community detection tool for knowledge graph partitioning

https://github.com/SDM-TIB/SemEP-Node

A demo reporting the behavior of state-of-the-art approaches for predicting interactions between drugs and targets

https://project-demo-bayer.herokuapp.com/indexpage/index.html



Partners Involved



THANK YOU!





















